- 1 Impact of intra-partum Azithromycin on carriage of group A streptococcus in The Gambia: a
- 2 posthoc analysis of a double-blind randomized placebo-controlled trial
- 3 Isatou Jagne¹
- 4 Email: <u>ijcox@mrc.gm</u>
- 5 Alexander J. Keeley³
- 6 Email: <u>a.keeley@sheffield.ac.uk</u>
- 7 Abdoulie Bojang¹
- 8 Email: <u>ambojang@mrc.gm</u>
- 9 Bully Camara¹
- 10 Email: <u>bcamara@mrc.gm</u>
- 11 Edrissa Jallow¹
- 12 Email: edjallow@mrc.gm
- 13 Elina Senghore¹
- 14 Email: <u>esenghore@mrc.gm</u>
- 15 Claire Oluwalana¹
- 16 Email: <u>coluwalana@mrc.gm</u>
- 17 Saikou Y. Bah^{1,3}
- 18 Email: <u>s.bah@sheffield.ac.uk</u>
- 19 Claire E. Turner³
- 20 Email: <u>c.e.turner@sheffield.ac.uk</u>
- 21 Abdul Karim Sesay¹
- 22 Email: <u>aksesay@mrc.gm</u>
- 23 Umberto D'Alessandro¹

- 24 Email: <u>udalessandro@mrc.gm</u>
- 25 Christian Bottomley²
- 26 Email: <u>christian.bottomley@lshtm.ac.uk</u>
- 27 Thushan I. de Silva^{1,3}
- 28 Email: <u>t.desilva@sheffield.ac.uk</u>
- 29 Anna $\operatorname{Roca}^{1^*}$
- 30 Email: <u>aroca@mrc.gm</u>
- 31

32 **Affiliations:**

- ¹ Medical Research Council Unit the Gambia at the London School of Hygiene and Tropical
- 34 Medicine, Banjul, The Gambia
- ² Faculty of Infectious and Tropical Diseases, London School of Hygiene & Tropical Medicine,
- 36 London, UK
- ³ The Florey Institute, University of Sheffield, Sheffield, UK.
- 38
- 39 *Corresponding Author: Disease Control and Elimination Theme, MRC Unit The Gambia at
- 40 the LSHTM, The Gambia
- 41 Short Title: Intra-partum azithromycin impact on GAS

42 Short Summary

- 43 Group A streptococcus (GAS) is an important cause of sepsis. One oral dose (2g) of intra-partum
- 44 azithromycin reduced maternal and neonatal GAS carriage. However, azithromycin-resistant
- 45 Streptococcus dysgalactiae subspecies equisimilis expressing Lancefield group A carbohydrate
- 46 was detected in women receiving azithromycin.

48 Abstract

Background: Group A Streptococcus (GAS) is a major human pathogen and an important cause of
 maternal and neonatal sepsis.

51 *Methods*: We performed a posthoc analysis of a double-blind, placebo-controlled randomized-trial (ratio

52 1:1) carried out in The Gambia to determine the impact of one oral dose (2g) of intra-partum

azithromycin on maternal and neonatal GAS carriage. Breast milk, nasopharyngeal and vaginal swabs

54 were collected at different time points during 4 weeks post-treatment. All samples were processed using

55 conventional microbiology techniques. Whole genome sequencing (WGS) of GAS isolates was

56 performed by Illumina MiSeq platform.

57 *Results*: We randomized 829 mothers who delivered 843 babies. GAS carriage in mothers in the

58 azithromycin arm was lower in breast milk (0.28% vs 2.48%, Prevalence Ratio (PR)=0.11, 95% CI 0.01-

59 0.90) and the nasopharynx (0.28% vs 1.93%, PR=0.15, 95% CI 0.02-1.19), but not in the vaginal tract

60 (1.99% vs 1.93%, PR=1.03, 95% CI 0.37-2.91). Among neonates, GAS carriage in the nasopharynx was

61 slightly lower in the azithromycin arm (0.57% vs 1.91%, PR=0.30, 95% CI 0.06-1.42). Prevalence of

62 azithromycin-resistant GAS was similar in both arms, except for a higher prevalence in the vaginal tract

63 among women in the azithromycin arm (1.99% vs 0.28%, PR=7.24, 95% CI 0.87-56.92). WGS revealed

ten of the 45 GAS isolates (22.2%) were *Streptococcus dysgalactiae* subspecies *equisimilis* expressing

Lancefield group A carbohydrate (SDSE(A)). All SDSE(A) isolates were azithromycin-resistant,

66 harbouring macrolide resistant genes *msrD* and *mefA*.

Conclusions: Oral intra-partum azithromycin reduced prevalence of GAS carriage among mothers and
 neonates. Azithromycin-resistant SDSE(A) carriage was observed among participants treated with
 azithromycin.

70 Trial registration: ClinicalTrials.gov Identifier NCT01800942

- 71 Keywords: Sub-Saharan Africa, azithromycin, bacterial carriage, group A *streptococcus*, *Streptococcus*
- 72 *dysgalactiae subspecies equisimilis*

74 BACKGROUND

75 Pregnant women and neonates are at highest risk of sepsis, up to 6 weeks after delivery, resulting in 6-76 19% of maternal deaths [1, 2]. Low- and middle-income countries (LMICs) have the highest burden of 77 mortality due to maternal sepsis, with the highest rates in sub-Saharan Africa (SSA). Neonatal sepsis is a 78 significant cause of severe morbidity and is estimated to cause 7% of under-5 mortality [3, 4]. Globally, 79 Staphylococcus aureus and Group B Streptococcus (GBS) are main causes of maternal and neonatal 80 sepsis [5-7]. Group A Streptococcus (GAS; Streptococcus pyogenes) is increasingly recognized as an 81 important Gram-positive pathogen associated with maternal and neonatal sepsis [8-10]. GAS can cause 82 both early and late onset of neonatal sepsis [11, 12], usually as a result of infection acquired through the 83 birth canal [12]. 84 Surveillance conducted in the USA between 1995 and 2000 estimated an annual incidence of 6 per 85 100,000 live births of GAS-related maternal sepsis, with a 3.5% case-fatality ratio in invasive disease 86 [13]. A review of pregnancy-related GAS infections between 1974 and 2009 included no data from SSA 87 [14]. Between 2010 and 2016, the incidence of GAS neonatal sepsis in London and the south of England 88 was 1.5 per 100,000 person years [15]. There is limited data on the burden of GAS infections in SSA due 89 to the lack of systematic surveillance [16]. In the Eastern Cape, South Africa, the mean annual incidence 90 rate of invasive GAS infection was 6 cases per 100,000-person years in all age groups (58% of samples 91 from 18-64 year olds) [17]. In Kenya, the incidence of neonatal GAS sepsis was 0.6 cases per 1,000 live 92 births [18]. GAS also causes non-invasive disease, including tonsillo-pharyngitis, skin infections and 93 rheumatic fever that can result in rheumatic heart disease [17, 19, 20]. 94 We conducted a double-blind randomized trial (the PregnAnZI trial) to assess the effect of 2g of oral 95 intra-partum azithromycin in reducing bacterial carriage of the main Gram-positive pathogens associated 96 with neonatal sepsis (S. aureus, Streptococcus pneumoniae and GBS) in the mother and the newborn 97 during the 4 weeks following the intervention [21]. The trial showed a consistent reduction of bacterial

- 98 carriage of these three bacteria in both the mother and their newborns during the entire neonatal period
- and a decrease in the occurrence of disease [22, 23]. We present here a posthoc analysis of the trial to
- 100 determine the effect of 2g intra-partum azithromycin on the prevalence and antibiotic resistance of GAS
- 101 in mothers and their newborns during the 4 weeks following the intervention. We also used whole
- 102 genome sequencing (WGS) to further characterise the GAS isolates and perform phylogenetic analysis.

103 METHODS

104 Study Design/Population

- 105 This study is a posthoc analysis of data from a double-blind, placebo-controlled randomized trial in which
- 106 women in labour were randomized to receive either a single dose of 2g of oral azithromycin or placebo
- 107 (ratio 1:1) [21]. The trial was conducted at the Jammeh Foundation for Peace (JFP), a government-run
- 108 health facility located in western Gambia that manages approximately 4,500 deliveries per year. The
- 109 population in the catchment area is representative of The Gambia and covers its main ethnic groups [22].
- Between April 2013 and April 2014, women aged 18-45 years attending the JFP labour ward and with no
- acute or chronic conditions were recruited into the trial. Details of exclusion criteria have been reported
- elsewhere [21]. The women had provided written informed consent to participate in the study during
- 113 previous antenatal care visits. Women and their newborns were followed for up to 8 weeks postpartum
- and biological samples were collected during the first 4 weeks [21, 22].

115 Study Samples

116 A nasopharyngeal swab (NPS) and a low vaginal swab (VS) were collected from women before the

117 intervention was administered and during labour. Post-intervention samples included: (i) newborn NPS

118 within 6 h after birth; (ii) samples collected during home visits at days 3, 6, 14 and 28 (NPS from mothers

and newborns, and breast milk(BM) from mothers) and (iii) a VS collected in the health facility during

the postnatal check at day 8-10 post-delivery [22].

122 Sample collection

- 123 NPS were collected by passing the tip of a calcium alginate (Expotech USA Inc) swab across the mucosa
- 124 of the posterior wall of the nasopharynx. The swab was rotated and left in the nasopharynx for
- approximately 5 seconds. The inoculated swab was placed immediately into a vial containing skim milk-
- tryptone-glucose-glycerol (STGG) transport medium and then into a cold box before being taken to the
- 127 Medical Research Council Unit The Gambia (MRC) at the London School of Hygiene and Tropical
- 128 Medicine (LSHTM) laboratories within 8 hours of collection [21].
- 129 VS were collected by inserting a sterile cotton swab (Sterilin Ltd, UK) 2–3 cm into the vagina and
- rotating the swab with a circular motion, leaving it in the vagina for approximately 5 seconds. The
- inoculated swabs were then placed immediately into the vials containing STGG and put in a cold box
- before being transferred to the MRC laboratories within 8 hours [21].
- Breast milk samples were collected by first disinfecting the nipple and areola of the breast using sterile
- 134 cotton soaked with 0.02 % chlorhexidine. Mothers were then asked to manually express their milk. The
- first 0.5 mL was discarded. The following 1-2 mL was collected in a sterile plastic bijoux bottle put in a
- 136 cold box and transferred to the MRC laboratories within 8 hours [21].

137 Laboratory Procedures

138 GAS culture from NPS, VS and breast milk samples

- 139 Samples were vortexed for 20 seconds prior to storage at -70° C for subsequent processing in batches.
- 140 During processing, samples were allowed to thaw on ice. Each vial was then vortexed briefly in order to
- homogenise the medium and 50µl was dispensed onto crystal violet blood agar (CVBA) (CM0085 Oxoid,
- 142 UK +0.02 % crystal violet) for selective isolation of beta-haemolytic streptococci [21].
- 143 After 20–24 h incubation, presumptive beta-haemolytic colonies were streaked onto blood agar to obtain
- a pure growth. A catalase test was performed to differentiate the presumptive streptococci from

145	staphylococci. Beta-haemolytic and catalase-negative isolates were grouped using the Streptex grouping
146	kit (Remel R30950501) and ultimately reported as group A, B, C, D, F or G [21].

147 Antimicrobial Susceptibility Testing

- 148 Pure morphologically similar colonies were made into a suspension equal to 0.5% MacFarland's standard
- and streaked evenly over the surface of Muller Hinton Agar (MHA). Antimicrobial resistance was
- evaluated using the disk diffusion method (15 ug azithromycin disk) and all resistant isolates(zones of
- inhibition ≤13mm) were confirmed using E-test (AZ 256,range 0.016-256ug/ml, Biomerieux) [21]. The
- 152 CLSI 2016 guidelines were used to interpret azithromycin susceptibility results.

153 Whole genome sequencing

- 154 Extracted DNA from all GAS isolates (isolated at any timepoint) was used for WGS by Illumina Miseq.
- 155 Paired end reads quality checked (FastQC) and trimmed for adaptor contaminant and low Q-score bases
- 156 (Trimmomatic), followed by *de novo* assembly using k-mer settings of 21, 22, 55 and 77 (SPAdes) [24,
- 157 25]. Assembled genomes were checked for post-assembly quality (QUAST) [26]. Criteria for inclusion in
- 158 further analysis were <500 contigs, 1.6-2.0Mb (*S. pyogenes*) or 2.0-2.4Mb (*Streptococcus dysgalactiae*
- subspecies *equisimilis*; SDSE) assembly length, and >90% reference genome coverage (*S. pyogenes*).
- 160 Assembled genomes were annotated using Prokka and the core genome determined using Roary [27,28].
- 161 Antimicrobial resistance genes were identified using ABRicate with the Resfinder database [29.30].
- 162 *Emm*-typing was performed using the bioinformatics method described at
- 163 <u>https://github.com/BenJamesMetcalf</u> and the CDC *emm*-typing database
- 164 (https://www2.cdc.gov/vaccines/biotech/strepblast.asp). Core genome alignments were used to draw
- 165 maximum likelihood phylogenetic trees (RAxML) with 1000 bootstraps [31]. For comparative
- 166 phylogenetic analysis of SDSE isolates, complete genomes were obtained from NCBI Genome resource
- 167 (<u>https://ncbi.nlm.nih.gov/genome/genomes/823?</u>) and from a previous study reporting SDSE expressing
- Lancefield group A (SDSE(A)) [32]. Phylogenetic trees were visualized using iTOL

169	(https://itol.embl.de/). All sec	juence data are	oublicly	y available at the	European	Nucleotide .	Archive
-----	------------------------	------------	-----------------	----------	--------------------	----------	--------------	---------

170 (project accession PRJEB36490).

171 Data Management and Statistical Analysis

- 172 The data was double entered into Open Clinica and analysed using STATA 16. We only included
- 173 participants with all samples collected at each of the specified timepoints. The prevalence of GAS
- 174 carriage was determined as the presence at any time point for each of the sample types. Prevalence was
- 175 compared between arms using prevalence ratios (PR) with their corresponding 95% confidence intervals
- 176 (CI). We used Fisher exact test to obtain p-values. Prevalence of azithromycin resistance was calculated
- 177 considering all sampled individuals as the denominator. If any isolate from a biological site was resistant,
- the sample of that participant was considered as resistant.

179 Ethical Approval

- 180 Ethical approval for the main trial was obtained from the Joint MRC Gambia Government Ethics
- 181 Committee. Ethical approval was given by LSHTM for the secondary data analysis.

182

183 **RESULTS**

184 Study Population

185 We recruited 829 women for the trial (414 women to the azithromycin and 415 to the placebo arms) who

delivered a total of 843 babies, including 13 stillbirths. Overall, 715 pairs (86.2%) had all study samples

- 187 collected and are part of this posthoc analysis (Figure 1). Most women were 20-29 years old and the
- 188 major ethnic group was Mandinka. Approximately 66.6% of deliveries occurred during the dry season

189 (November to May), 5.0% of the newborns were low-birth weight and slightly more than half were males

190 (Table 1).

191 Prevalence of GAS carriage

- 192 Overall, 30 women and 9 newborns had at least 1 sample positive for GAS; 7 women and one baby had 2
- 193 positive samples and one woman had 5 positive samples (Total of 51 GAS isolates).
- 194 *Study mothers*. Pre-intervention prevalence of GAS was low and similar in the two study arms, both in the
- 195 nasopharynx and in the vaginal tract (Table 2, Figure 2a). Post intervention, prevalence of GAS in the
- azithromycin arm was lower in the nasopharynx (0.28% versus 1.93%, PR=0.15 95% CI (0.02,1.19),
- 197 p=0.069) and breast milk (0.28% versus 2.48%, PR=0.11 95% CI (0.01,0.90), p=0.021) but not in the

198 vaginal tract (1.99% versus 1.93%, PR=1.03 95% CI (0.37,2.91), p=1.000) (Table 2).

199 Study newborns. Prevalence of nasopharyngeal carriage of GAS was low; with a lower prevalence in the

200 azithromycin arm (0.57% versus 1.91%, PR=0.30 95% CI (0.06,1.42), p=0.178) (Table 2, Figure 2b).

201 **Prevalence of azithromycin resistance**

- 202 *Study mothers*. Prevalence of azithromycin-resistant GAS was similar between study arms for all sample
- types except for higher resistance in vaginal GAS isolates in the intervention arm [1.99% vs. 0.28%,

204 PR=7.24, 95% CI (0.87,56.92 p=0.035)] (Table 3).

Study newborns. Prevalence of GAS azithromycin resistance was low and similar between arms with only
 two participants having resistant GAS isolates (Table 3).

207 Whole Genome Sequencing

208 Of the 51 GAS isolates, one sample was not retrieved and five samples (isolated from four mothers) had

- 209 poor sequences and were excluded from the WGS analysis. Of the remaining 45 isolates, WGS confirmed
- 210 that 35 were *S. pyogenes* (2 from the azithromycin arm and 33 from the placebo arm of the trial), from
- which we detected 16 emm types. The most common were emm4 and emm44 (5 isolates each, 14.2%) and
- *emm*147 (4 isolates, 11.4%). The remaining 10 isolates were SDSE. All were phenotypically resistant to

213	azithromycin and 9 were from participants in the azithromycin arm. All 10 SDSE(A) isolates were
214	retested with Streptex grouping kit and were confirmed as Lancefield group A beta-haemolytic
215	streptococci. We observed that the most common resistance mechanism was by efflux with 14 out of 16
216	azithromycin-resistant isolates (including all SDSE(A)) harbouring both mefA and msrD genes (mefA-
217	msrD). In S. pyogenes, mefA and msrD genes were adjacent to each other and located five genes
218	upstream of catQ on what appeared to be a phage-like mobile genetic element, integrated downstream of
219	rlmD (23s rRNA methyltransferase). In SDSE(A), mefA and msrD were also present on a mobile genetic
220	element that showed some similarity to that found in the reference SDSE strain AC-2713 (HE858529.1)
221	integrated between comEC and comEA, but differed in gene content between the two lineages of
222	SDSE(A). The complete sequences of the mobile elements for both S. pyogenes and SDSE(A) could not
223	be determined due to contig breaks in the <i>de novo</i> assemblies. S. pyogenes isolates recovered from the
224	same mother from different biological sites or study timepoints, as well as isolates from their new-borns,
225	all clustered together and belonged to the same emm type (Figure 3a). Similar phylogenetic and
226	epidemiological concordance was seen in the SDSE(A) isolates, including a neonatal NPS isolate closely
227	linked to those recovered from the baby's mother (Figure 3b).

228

229 **DISCUSSION**

One oral dose (2g) of azithromycin given to women in labour reduced the prevalence of GAS carriage among women and their babies in the nasopharynx and breast milk without an increase of azithromycin resistance in isolates in these sample sites. In contrast, the intervention did not have any effect on the prevalence of GAS carriage in the vaginal tract but induced an increase in the carriage prevalence of azithromycin-resistant SDSE(A).

We have previously shown that a single oral dose (2g) of azithromycin given to women in labour reduced the prevalence of *S. aureus, S. pneumoniae* and GBS carriage in the mother (nasopharynx, breast milk and

vaginal tract) and the baby (nasopharynx) [22]. The current analysis shows that the intervention also
reduced the prevalence of GAS carriage in the breast milk and nasopharynx of study women and, less
clearly, in the nasopharynx of their newborns. Despite substantial reduction of GAS carriage, we did not
observe any short-term increase of azithromycin resistance in these two biological sites.

241 Conversely, the intervention did not have any effect on the prevalence of GAS carriage in the maternal 242 vaginal tract but induced an increase in azithromycin resistance. WGS revealed that GAS vaginal carriage 243 in the azithromycin arm was primarily due to azithromycin-resistant SDSE(A), whereas in the placebo 244 arm, GAS vaginal carriage was entirely due to azithromycin-susceptible S. pyogenes. In our previous 245 analysis on S. aureus, lower reduction in carriage in the vaginal tract alongside a higher prevalence of 246 resistance was also observed [22]. It is not clear why the effect of the intervention in the vaginal tract 247 differs from other body sites. The concentration of azithromycin in the vaginal tract may be lower and fall 248 more rapidly than in other biological sites. We had previously shown a very high concentration of 249 azithromycin in breast milk during the 4 weeks following the intervention, with a peak during the first 6 250 days (concentration >4.000 µg/L) [33]. A different study using a single dose of azithromycin (1g) 251 showed the azithromycin concentration in the vaginal tract was much lower than the breast milk 252 concentration we observed [34]. In this study, the peak concentration occurred during the first 24-48 253 hours following the intervention [34], long before the post-intervention VS were collected in our study. It 254 is possible that removal of S. pyogenes from the vaginal tract allows azithromycin-resistant SDSE to 255 thrive, whereas in other body sites higher concentrations of azithromycin can overcome the efflux-256 mediated resistance mechanisms [35]. An alternative explanation is that even though SDSE can be found 257 in different biological sites, it is better suited to survive in the vaginal tract [36]. One azithromycin-258 resistant SDSE(A) was isolated in the vaginal tract from a woman included in the azithromycin arm 259 before the intervention was administered. A phylogenetically-linked isolate was isolated from the same 260 woman's VS after the intervention.

261 The public health and clinical implications of the selective expansion of SDSE(A) in the vaginal tract are 262 difficult to anticipate. However, similarly to S. pyogenes, SDSE can cause invasive disease [37-39]. 263 Lancefield group A SDSE has been described in previous studies from high income settings, including a 264 collection of isolates causing invasive disease in the USA [32]. The SDSE(A) isolated from our study 265 participants have distinct phylogeny to SDSE(A) previously isolated in USA and fall into two distinct 266 clades. In our study, all SDSE(A) isolates harboured *mefA-msrD* genes, whereas both erm(B) and *mefA-*267 *msrD* genes were found in azithromycin-resistant S. pyogenes isolates. While the presence of *mefA* is 268 associated with macrolide resistance, *msrD* has a more dominant role [40, 41]. The presence of both *mefA* 269 and *msrD* may confer high level resistance [41]. 270 The trial was designed to evaluate the effect of intra-partum azithromycin on maternal and neonatal 271 carriage of S. aureus, S. pneumoniae and GBS that are more prevalent than S. pyogenes and therefore the 272 current analysis was underpowered as observed in the comparison of trial arms in the nasopharyngeal 273 swabs, especially in newborns. This was an opportunistic study and oropharyngeal rather than 274 nasopharyngeal samples may have been more appropriate for detecting S. pyogenes carriage [42], but

- adds to the growing evidence that group A *Streptococcus* may include SDSE as well as *S. pyogenes*.
- 276 In conclusion, this study demonstrates that a simple intervention (single dose of intra-partum oral
- 277 azithromycin), besides reducing carriage of *S. aureus, S. pneumoniae* and GBS, can also reduce carriage
- of GAS, an important cause of maternal and neonatal sepsis. We need to closely monitor the effect of this
- 279 prophylactic intervention on azithromycin-resistant SDSE(A) isolates and its effect on disease when
- assessing the overall public health potential of prophylactic intra-partum azithromycin.
- 281 Supplementary Data
- 282 Supplementary 1: WGS_data.xlsx

283

284 Author's contributions

AR and UDA conceived and designed the initial trial. AR, IJ and TdS conceived this posthoc study. IJ wrote the manuscript and AR, TdS, AJK contributed significantly in the final version. CO, BC, AB developed and adapted the field and laboratory work. IJ, EJ and ES analysed the samples. AKS led the team that conducted the WGS. AJK, SYB, CET and TdS performed the WGS analysis. CB provided statistical input to the study. All authors read and approved the final manuscript.

290 Acknowledgements

The authors express our profound gratitude to the study participants and their families for agreeing to take part in the study. We give special thanks to the laboratory team (Njemmeh Manneh, Aji Mary Taal, Aru Kumba Baldeh, Modou Lamin Fofana, Momodou Abass Bah and Nano Kora) for their involvement in sample reception and processing. We also extend our gratitude to Jarra Manneh and Abdoulie Kanteh of the MRCG genomics team, Nuredin Ibrahim Mohammed for assisting with generating some figures and the field team (led by Edrissa Sabally and Omar Jarra) for assisting with sample collection.

297 Financial support

The MRC Unit in The Gambia at LSHTM receives core funding from the MRC UK. The trial was jointly funded by the MRC UK and the UK Department for International Development (DFID) under the MRC/DFID Concordat agreement (reference number MR/J010391/1). The WGS was funded by a HEFCE/ODA grant from The University of Sheffield (155123). TdS is funded by a Wellcome Trust Intermediate Clinical Fellowship (110058/Z/15/Z). CET is a Royal Society & Wellcome Trust Sir Henry Dale Fellow (208765/Z/17/Z).

304 Potential conflicts of interest

305 All authors declare no conflicts of interest

307 **References**

308	1.	WHO. Maternal Sepsis. Available at: https://www.who.int/reproductivehealth/maternal-

- 309 <u>sepsis/en/</u>. Accessed 10/02/2018.
- 310 2. Say L, Chou D, Gemmill A, et al. Global causes of maternal death: a WHO systematic analysis.
- 311 Lancet Glob Health **2014**; 2(6): e323-33.
- 3. Shah BA, Padbury JF. Neonatal sepsis: an old problem with new insights. Virulence **2014**; 5(1):
 170-8.
- UNICEF. Under-five Mortality. Available at: <u>https://data.unicef.org/topic/child-survival/under-</u>
 five-mortality/. Accessed 20/01/2020.
- 5. Knowles SJ, O'Sullivan NP, Meenan AM, Hanniffy R, Robson M. Maternal sepsis incidence,
- aetiology and outcome for mother and fetus: a prospective study. BJOG **2015**; 122(5): 663-71.
- 318 6. Simonsen KA, Anderson-Berry AL, Delair SF, Davies HD. Early-onset neonatal sepsis. Clin
- 319 Microbiol Rev **2014**; 27(1): 21-47.
- 320 7. Okomo U, Akpalu ENK, Le Doare K, et al. Aetiology of invasive bacterial infection and
- 321 antimicrobial resistance in neonates in sub-Saharan Africa: a systematic review and meta-
- 322 analysis in line with the STROBE-NI reporting guidelines. The Lancet Infectious Diseases **2019**;
- **323 19(11)**: **1219-34**.
- 8. Ekelund K, Skinhoj P, Madsen J, Konradsen HB. Invasive group A, B, C and G streptococcal
- 325 infections in Denmark 1999-2002: epidemiological and clinical aspects. Clin Microbiol Infect
- **2005**; 11(7): 569-76.

327	9.	Rantala S, Vu	opio-Varkila J, Vuen	to R, Huhtala H	, Syrjanen J.	Clinical presentations and
-----	----	---------------	----------------------	-----------------	---------------	----------------------------

- 328 epidemiology of beta-haemolytic streptococcal bacteraemia: a population-based study. Clin
- 329 Microbiol Infect **2009**; 15(3): 286-8.
- 330 10. Anderson BL. Puerperal group A streptococcal infection: beyond Semmelweis. Obstet Gynecol
 331 2014; 123(4): 874-82.
- Ronchetti MP, Bersani I, Piersigilli F, Auriti C. Neonatal Sepsis. Archives of Paediatrics and
 Developmental Pathology **2017**; 1(3): 1015.
- Revelas A, Taxmazidis O. Group A streptococcal infections in children. Southern African Journal
 of Epidemiology and Infection **2015**; 27(3): 98-103.
- 13. Chuang I, Van Beneden C, Beall B, Schuchat A. Population-based surveillance for postpartum
 invasive group a streptococcus infections, 1995-2000. Clin Infect Dis 2002; 35(6): 665-70.
- 14. Hamilton SM, Stevens DL, Bryant AE. Pregnancy-related group a streptococcal infections:
- 339 temporal relationships between bacterial acquisition, infection onset, clinical findings, and
- 340 outcome. Clin Infect Dis **2013**; 57(6): 870-6.
- 15. Leonard A, Wright A, Saavedra-Campos M, et al. Severe group A streptococcal infections in
 mothers and their newborns in London and the South East, 2010-2016: assessment of risk and
- audit of public health management. BJOG **2019**; 126(1): 44-53.
- Barth DD, Engel ME, Whitelaw A, et al. Rationale and design of the African group A streptococcal
 infection registry: the AFROStrep study. BMJ Open **2016**; 6(2): e010248.

346	17.	Barth D, M Mayosi B, Badri M, Whitelaw A, E Engel M. Invasive and non-invasive group A eta -
347		haemolytic streptococcal infections in patients attending public sector facilities in South Africa:
348		2003–2015. Southern African Journal of Infectious Diseases 2017 ; 33(1): 12-7.
349	18.	Seale AC, Davies MR, Anampiu K, et al. Invasive Group A Streptococcus Infection among
350		Children, Rural Kenya. Emerg Infect Dis 2016 ; 22(2): 224-32.
351	19.	Belard S, Toepfner N, Arnold B, Alabi AS, Berner R. beta-Hemolytic streptococcal throat carriage
352		and tonsillopharyngitis: a cross-sectional prevalence study in Gabon, Central Africa. Infection
353		2015 ; 43(2): 177-83.
354	20.	Armitage EP, Senghore E, Darboe S, et al. High burden and seasonal variation of paediatric
355		scabies and pyoderma prevalence in The Gambia: A cross-sectional study. PLoS Negl Trop Dis
356		2019 ; 13(10): e0007801.
357	21.	Roca A, Oluwalana C, Camara B, et al. Prevention of bacterial infections in the newborn by pre-
357 358	21.	Roca A, Oluwalana C, Camara B, et al. Prevention of bacterial infections in the newborn by pre- delivery administration of azithromycin: Study protocol of a randomized efficacy trial. BMC
	21.	
358	21.	delivery administration of azithromycin: Study protocol of a randomized efficacy trial. BMC
358 359		delivery administration of azithromycin: Study protocol of a randomized efficacy trial. BMC Pregnancy Childbirth 2015 ; 15: 302.
358 359 360		delivery administration of azithromycin: Study protocol of a randomized efficacy trial. BMC Pregnancy Childbirth 2015 ; 15: 302. Roca A, Oluwalana C, Bojang A, et al. Oral azithromycin given during labour decreases bacterial
358 359 360 361		delivery administration of azithromycin: Study protocol of a randomized efficacy trial. BMC Pregnancy Childbirth 2015 ; 15: 302. Roca A, Oluwalana C, Bojang A, et al. Oral azithromycin given during labour decreases bacterial carriage in the mothers and their offspring: a double-blind randomized trial. Clin Microbiol Infect
358 359 360 361 362	22.	delivery administration of azithromycin: Study protocol of a randomized efficacy trial. BMC Pregnancy Childbirth 2015 ; 15: 302. Roca A, Oluwalana C, Bojang A, et al. Oral azithromycin given during labour decreases bacterial carriage in the mothers and their offspring: a double-blind randomized trial. Clin Microbiol Infect 2016 ; 22(6): 565 e1-9.
358 359 360 361 362 363	22.	 delivery administration of azithromycin: Study protocol of a randomized efficacy trial. BMC Pregnancy Childbirth 2015; 15: 302. Roca A, Oluwalana C, Bojang A, et al. Oral azithromycin given during labour decreases bacterial carriage in the mothers and their offspring: a double-blind randomized trial. Clin Microbiol Infect 2016; 22(6): 565 e1-9. Oluwalana C, Camara B, Bottomley C, et al. Azithromycin in Labor Lowers Clinical Infections in

- 367 25. Bankevich A, Nurk S, Antipov D, et al. SPAdes: a new genome assembly algorithm and its
- 368 applications to single-cell sequencing. Journal of computational biology : a journal of
- 369 computational molecular cell biology **2012**; 19(5): 455-77.
- 370 26. Gurevich A, Saveliev V, Vyahhi N, Tesler G. QUAST: quality assessment tool for genome
- 371 assemblies. Bioinformatics **2013**; 29(8): 1072-5.
- 372 27. Seemann T. Prokka: rapid prokaryotic genome annotation. Bioinformatics **2014**; 30(14): 2068-9.
- 28. Page AJ, Cummins CA, Hunt M, et al. Roary: rapid large-scale prokaryote pan genome analysis.
- Bioinformatics **2015**; 31(22): 3691-3.
- Zankari E, Hasman H, Cosentino S, et al. Identification of acquired antimicrobial resistance
 genes. J Antimicrob Chemother **2012**; 67(11): 2640-4.
- 377 30. Karsnitz DB. Puerperal infections of the genital tract: a clinical review. J Midwifery Womens
 378 Health **2013**; 58(6): 632-42.
- 379 31. Stamatakis A. RAxML version 8: a tool for phylogenetic analysis and post-analysis of large
- 380 phylogenies. Bioinformatics (Oxford, England) **2014**; 30(9): 1312-3.
- 381 32. Chochua S, Rivers J, Mathis S, et al. Emergent Invasive Group A Streptococcus dysgalactiae
 382 subsp. equisimilis, United States, 2015-2018. Emerg Infect Dis 2019; 25(8): 1543-7.
- 383 33. Salman S, Davis TM, Page-Sharp M, et al. Pharmacokinetics of Transfer of Azithromycin into the
- Breast Milk of African Mothers. Antimicrob Agents Chemother **2015**; 60(3): 1592-9.
- 385 34. Vodstrcil LA, Rupasinghe TWT, Kong FYS, et al. Measurement of tissue azithromycin levels in
- 386 self-collected vaginal swabs post treatment using liquid chromatography and tandem mass
- 387 spectrometry (LC-MS/MS). PLoS One **2017**; 12(5): e0177615.

388	35.	Levison ME, Levison JH. Pharmacokinetics and pharmacodynamics of antibacterial agents.
389		Infectious disease clinics of North America 2009 ; 23(4): 791-vii.
390	36.	Ciszewski M, Szewczyk EM. Potential Factors Enabling Human Body Colonization by Animal
391		Streptococcus dysgalactiae subsp. equisimilis Strains. Current microbiology 2017 ; 74(5): 650-4.
392	37.	Yamaoka S, Ogihara T, Yasui M, et al. Neonatal streptococcal toxic shock syndrome caused by
393		Streptococcus dysgalactiae subsp. equisimilis. Pediatr Infect Dis J 2010 ; 29(10): 979-81.
394	38.	Watanabe S, Takemoto N, Ogura K, Miyoshi-Akiyama T. Severe invasive streptococcal infection
395		by Streptococcus pyogenes and Streptococcus dysgalactiae subsp. equisimilis. Microbiol
396		Immunol 2016 ; 60(1): 1-9.
397	39.	Loubinoux J, Plainvert C, Collobert G, et al. Adult invasive and noninvasive infections due to
398		Streptococcus dysgalactiae subsp. equisimilis in France from 2006 to 2010. J Clin Microbiol 2013;
399		51(8): 2724-7.
400	40.	Zhang Y, Tatsuno I, Okada R, et al. Predominant role of msr(D) over mef(A) in macrolide
401		resistance in Streptococcus pyogenes. Microbiology 2016 ; 162(1): 46-52.
402	41.	Tatsuno I, Isaka M, Masuno K, Hata N, Matsumoto M, Hasegawa T. Functional Predominance of
403		msr(D), Which Is More Effective as mef(A)-Associated Than mef(E)-Associated, Over
404		mef(A)/mef(E) in Macrolide Resistance in Streptococcus pyogenes. Microb Drug Resist 2018 ;
405		24(8): 1089-97.
406	42.	Martin J. The Streptococcus pyogenes Carrier State. In: Ferretti JJ, Stevens DL, Fischetti VA.
407		Streptococcus pyogenes : Basic Biology to Clinical Manifestations. Oklahoma City (OK), 2016 .
408		

Characteristics		Placebo n (%)	Azithromycin n (%)
Mothers		n = 363	n = 352
Age	18-19 years	32 (8.8)	20 (5.7)
	20-29 years	239 (65.8)	229 (65.1)
	≥30 years	92 (25.3)	103 (29.3)
Ethnicity ^a	Mandinka	160 (44.1)	140 (39.8)
	Wolof	42 (11.6)	42 (11.8)
	Jola	53 (14.6)	62 (17.6)
	Fula	57 (15.7)	62 (17.6)
	Other	51 (14.1)	43 (12.2)
Season of Delivery	Dry (Nov – May)	244 (67.2)	232 (65.9)
	Rainy (June – Oct)	119 (32.8)	120 (34.1)
Newborns		n = 366	n = 352
Birth weight	Low birth weight(<2.5kg)	23 (6.3)	13 (3.7)
	Normal birth weight(>2.5kg)	338 (93.7)	338 (96.3)
Apgar Score	0	0	0
(at birth)	1-6	3 (0.8)	1 (0.3)
	7 – 10	362 (98.9)	350 (99.4)
Sex of child	Male	195 (53.3)	180 (51.1)
	Female	171 (46.7)	172 (48.9)

410 Table 1: Baseline Demographic Characteristics of study participants

411 ^aEthnicity missing in n=3, ^bApgar score in n=2

Table 2: Prevalence of GAS carriage in the nasopharynx, breastmilk and vaginal samples of mothers and
 nasopharynx of babies

cebo (%) Aziti 363 $n = 3$ Nasoph 1 (0.	352 (9 aryngeal carriage	95% CI)	p-value					
363 n = 3 Nasoph 1 (0.	352 (9 aryngeal carriage	95% CI)	p-value					
Nasoph 1 (0.	aryngeal carriage							
1 (0.	• • • •							
	- 28)							
	/		0.492					
	28) 0.	15 (0.02,1.19)	0.069					
Breastmilk carriage ^c								
2.48) 1 (0.	28) 0.	11 (0.01,0.90)	0.021					
Vag	ginal carriage							
).28) 2 (0.	57) 2	.06 (0.18,22.64)	0.619					
.93) 7 (1.	99) 1.	03 (0.37, 2.91)	1.000					
N	EWBORNS							
cebo (%) Azitl	hromycin (%) Pr	revalence Ratio	p value					
366 n = 3	352 (9	95% CI)						
.91) 2 (0.5	57) 0.2	30 (0 06 1 42)	0.178					
	$\begin{array}{c} 2.48) & 1 (0. \\ \hline Vag \\ 0.28) & 2 (0. \\ .93) & 7 (1. \\ \hline N \\ cebo (\%) & Azitt \\ 366 & n = 3 \\ \end{array}$	Vaginal carriage 0.28) $2 (0.57)$ 2 $.93$) $7 (1.99)$ 1 NEWBORNS cebo (%) Azithromycin (%) Pr 366 $n = 352$ (9)	2.48) 1 (0.28) 0.11 (0.01,0.90) Vaginal carriage 0.28) 2 (0.57) 2.06 (0.18,22.64) .93) 7 (1.99) 1.03 (0.37, 2.91) NEWBORNS cebo (%) Azithromycin (%) Prevalence Ratio 366 n = 352 (95% CI)					

414 ^aCarriage at day 0 before treatment

415 ^bCarriage at days 3, 6, 14 and 28 combined

416 ^c There are no pre-intervention samples for the breast milk

417 ^dDay 10(day 8 - 13)

- 418 ^eDay 0, 3,6,14 and 28 combined. Day 0 is the day of birth
- 419
- 420 Table 3: Prevalence of carriage of resistant GAS in the nasopharynx, breastmilk and vaginal
- 421 samples of mothers and nasopharynx of babies.
- 422 ^aCarriage at day 0 before treatment

		MOTHERS		
	Placebo (%)	Azithromycin (%)	Prevalence Ratio	p-value
	n = 363	n = 352	(95% CI)	
	Ν	asopharyngeal carri	age	
Pre-intervention ^a	0	0	-	-
Post-Intervention ^b	2 (0.55)	1 (0.28)	0.52 (0.05,5.66)	1.000
		Breastmilk carriage	⁵ c	
Post-Intervention ^b	0	1 (0.28)	-	0.492
		Vaginal carriage		
Pre-intervention ^a	0	1 (0.28)	-	-
Post-Intervention ^d	1 (0.28)	7 (1.99)	7.24 (0.87,56.92)	0.035
		NEWBORNS		
	Placebo (%)	Azithromycin (%)	Prevalence Ratio	p value
	n = 366	n = 352	(95% CI)	
Post-intervention ^e	1 (0.27)	1 (0.28)	1.04 (0.07,16.56)	1.000

423 ^bCarriage at days 3, 6, 14 and 28 combined

424 ^c There are no pre-intervention samples for the breast milk


425 ^dDay 10(day 8 - 13)

426 ^eDay 0, 3,6,14 and 28 combined. Day 0 is the day of birth


- Figure 1: Trial profile 1 Mother/baby pair with ≥ 1 missing sample


- 431 Figure 2: (a) Prevalence of i) maternal nasopharyngeal carriage and ii) breastmilk carriage of
- 432 GAS at different timepoints in the azithromycin and placebo arms. (b) Prevalence of neonatal
- asopharyngeal carriage of GAS at different timepoints in the azithromycin and placebo arms

- 435 Figures 3: Midpoint rooted maximum likelihood core-genome phylogenetic analysis using
- 436 RAXML GTRCAT model with 1000 bootstrap replicates. Circle symbols indicate >99%
- 437 bootstrap support. (a) Core-genome (1299 genes) phylogenetic analysis of 35 S. pyogenes isolates
- 438 from the study cohort. (b) International contextualization (based on core genome of 1221 genes)
- 439 of 10 *S. dysgalactiae* subspecies *equisimilis* isolates with individual core-genome (upper clade:
- 440 2106 genes, lower clade: 2078 genes) phylogenetic analysis of the two distinct clades in the
- study cohort. (Annotation key: country of origin; black=the Gambia, yellow=USA, dark
- 442 green=UK, light green=Germany, pink=Japan, white=unknown, symbols; filled=present,
- unfilled=absent, no symbol=unknown; study participant ID (unique study identifier for
- 444 mother/baby units); M=mother, B=newborn, NPS=nasopharyngeal swab, VS=vaginal swab,
- 445 BM=breast milk, AMR=antimicrobial resistance).




NPS






NPS



0.001

	Emm type	Study participant ID	Azithromycin Study arm	Day of sample	Site of sample	Phenotypic azithromycin resistance	(6)-III 1(3) 1(B) (pC194) (pC194) (m) (I) (I) (I) (I) (I)
8689-9 704-3 M2202-4 6719-3 5971-2 6330-5 6329-3 1761-9 4556-7 10025-4 4389-5 9455-2 5225-2 A668-4 6026-6 9517-4 1368-3 M3483-6 6250-5 8015-8 2408-1 2251-8 5280-7 3270-6 9978-4 MB494-4 3378-4 M1152-6 M1152-6 M1152-6 M1152-6 M1152-6 M1152-6 M1299-1 M0032-8 8522-2 M2588-7 M0269-6 257-4	emm57 emm122 emm80 emm147 emm147 emm147 emm147 emm148 emm44 emm44 emm44 emm44 emm41 emm103 emm103 emm103 emm103 emm11 emm11 emm11 emm11 emm11 emm11 emm11 emm13 emm73 emm73 emm73 emm73 emm73 emm73	M 663/7 M 573/7 M 467/2 M 500/5 B 500/5 M 500/5 M 133/1 M 375/7 M 827/4 B 337/4 B 337/4 M 756/4 M 361/2 M 778/7 M 108/4 M 792/2 B 451/2 B 594/7 M 108/4 M 792/2 B 451/2 B 594/7 M 202/3 M 433/2 M 433/2 M 260/3 B 763/2 M 787/4 M 763/2 M 787/4 M 763/2 M 787/4 M 763/2 M 179/1 M 179/1 M 179/1 M 179/1 M 179/1 M 179/1 M 179/1 M 179/1 M 179/1 M 179/1		28 83 28 61 41 86 81 82 14 88 61 14 88 61 14 14 63	NPS VS BNPS NPS VS NPS VS NPS VS NPS VS NPS NPS NPS NPS NPS NPS NPS NPS NPS NP		





0.001

_____SRR7706919

	Study participant ID	Azithromycin Study arm Placebo	Day of sample	Site of sample	Phenotypic azithromycin resistance
3062-4 2559-9 2994-1 2638-7	M 222/9 B 227/0 M 227/0 M 227/0		8 6 8 0	VS NPS VS VS	
7115-3 5635-6 4061-9 2221-7 1367-2 M0412-0	M 739/4 M 455/9 M 320/9 M 166/0 M 107/3 M 107/3		3 8 8 14	NPS VS VS VS BM	

